SOSAFE-GMBH
SoSafe, Europe’s leading vendor for security awareness, behavior, and culture change, today announced the appointment of Andrew Rose as its new Chief Security Officer (CSO). With a wealth of experience in the industry, Rose is a highly accomplished cyber security executive with a strong focus on the people-centric aspects of cyber security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240207094549/en/
Andrew Rose appointed as new Chief Security Officer at leading security awareness vendor SoSafe (Photo: Business Wire)
In his role as CSO, Rose will focus on driving SoSafe’s vision to strengthen digital self-defense worldwide and help customers transform their security culture. He’ll also bring hands-on experience, knowledge, and perspective in managing risk and improving cyber security posture across complex enterprises.
Recognized for his outstanding contributions to the field, Rose was awarded the prestigious title of 'European CISO of the Year 2018' at the SC Awards, and has been a part of the CSO30 every year since its inception in 2020. Across his career, Rose has transformed security management for multiple major organizations in the legal, aviation, technology, and finance sectors.
Notably, Rose held the position as Resident CISO at Proofpoint Inc., where he helped customers enhance their security practices, cultivated a community of CISOs and represented the brand externally. Prior to that, he oversaw the cyber security of UK airspace traffic at NATS and managed the secure processing of trillions of pounds in transfers at Vocalink, a Mastercard company. He also worked at Forrester Research, where he was Principal Analyst covering the awareness and culture change space and developed influential models for the security awareness industry. In 2015, when Rose implemented the models he had designed at Forrester, he was awarded ‘UK Awareness Campaign of the Year’ at the UK Cyber Security Awards. Rose also has an established record in the legal sector with over a decade as CISO at 'magic circle' firms Clifford Chance LLP and Allen & Overy LLP.
Niklas Hellemann, Psychologist and CEO of SoSafe, remarked: "Andrew’s expertise is a perfect match for our mission at SoSafe. In an era where AI-powered cyber threats are escalating, Andrew's extensive industry experience is invaluable in leading our efforts to be the global industry leader in fortifying the human aspect of cyber security.”
Rose's decision to join SoSafe was driven by the company's unwavering focus on addressing the critical problem of the underestimated human factor in cyber security. “There is a huge imbalance in focus as the biggest part of security budgets are dedicated to security technology while according to the World Economic Forum, 95% of cyber threats have a human element involved. SoSafe’s commitment to strengthening the human factor, coupled with their innovative use of behavioral science and technology, aligns perfectly with my vision.”
“SoSafe’s approach to security awareness is unique in the industry: Having a CEO with a background in psychology means that the human-centric perspective is deeply rooted in their DNA. They focus on behavioral science to tackle the problem and then use technology to enable the solution”, Rose stated.
By joining SoSafe, Andrew Rose will further strengthen the company's position as a leader in the industry. With his track record of success and commitment to driving secure behavior in organizations, Andrew Rose is poised to make a significant contribution to the company's ongoing mission of strengthening digital self-defense.
About SoSafe
SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by Dr Niklas Hellemann, Lukas Schaefer, and Felix Schuerholz. Today, it serves more than 4500 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team consists of more than 370 employees at seven locations: Cologne (headquarters), Amsterdam, Berlin, Lisbon, London, Munich, and Paris.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207094549/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
